Iovance Biotherapeutics (0JDK) AI Stock Analysis

5 Followers

Iovance Biotherapeutics

(LSE:0JDK)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Commercial Revenue GrowthRapid revenue growth and more than 1,000 commercial patients treated indicate expanding adoption of AMTAGVI rather than an unlaunched pipeline story. Continued sequential growth and reaffirmed guidance improve commercial visibility while strengthening the base for broader treatment-center utilization.

Negative Factors

Persistent Operating LossesIovance has not yet demonstrated sustainable earnings power despite commercial revenue growth, and management did not provide a timeline for profitability. Continued operating losses could constrain reinvestment choices and leave results dependent on further scale, margin gains, and disciplined expenses.

Iovance Biotherapeutics (0JDK) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $3.74B
Dividend Yield: ―
Average Volume (3M): 139.37K
Price to Earnings (P/E): -15.3
Beta (1Y): 0.87
Revenue Growth: 51.31%
EPS Growth: 56.78%
Country: UK
Employees: 975
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Iovance Biotherapeutics Business Overview & Revenue Model

Company Description

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system t...

Iovance Biotherapeutics Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-7.65%|Next Earnings Date:Mar 02, 2027

Earnings Call SentimentPositive

The call was strongly positive, supported by record revenue, AMTAGVI adoption, expanding treatment-center access, record margin, an extended cash runway, and encouraging clinical and regulatory progress across multiple pipeline programs. The principal negatives were the continuing operating loss, maturing durability data in lung cancer, and pending international reimbursement and regulatory steps. Overall, highlights significantly outweighed lowlights.

Positive Updates

Record Quarterly Revenue

Third-quarter total revenue reached approximately $122 million, up 80% year over year and 22% sequentially, setting a new quarterly record.

Negative Updates

Company Remains at an Operating Loss

The company reported a quarterly operating loss of approximately $24 million and an EPS loss of $0.05. Management said Iovance is on its way to profitability but did not provide timing for achieving it.

Company Guidance

Iovance reaffirmed full-year 2026 revenue guidance of $410 million-$420 million, expects growth quarter-over-quarter, plans to reach 110 or more authorized treatment centers by year-end, expects margin to expand further over time, and expects cash to fund operations well into 2029; Proleukin’s trend is expected to continue in Q4. The company plans to complete IOV-LUN-202 at 80 patients, submit the lung cancer sBLA in 2027, enroll 80 patients in POSITILITY beginning this month, and plan OPTILISM in 2027; SARATOGA is expected to enroll 40 patients in each cohort, with sBLA submissions planned for 2028 or 2029. Potential approvals in the U.K. and Switzerland are expected by the first quarter of 2027, with a Brazil application and European Union resubmission planned in 2027.

Iovance Biotherapeutics Risk Analysis

Iovance Biotherapeutics disclosed 85 risk factors in its most recent earnings report. Iovance Biotherapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks

1.Inflation RiskQ2, 2026

2.Foreign currency exchange riskQ2, 2026

Iovance Biotherapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0JDK against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMCR	52Neutral	$1.67B	-50.01	-7.96%	―	13.01%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NKTR	49Neutral	$1.29B	-5.74	-37.99%	―	-27.15%	23.10%
NUVB	49Neutral	$1.49B	-10.87	-49.11%	―	654.19%	39.07%
IMTX	47Neutral	$960.66M	-3.61	-52.19%	―	-44.50%	-80.18%
RCUS	45Neutral	$2.69B	-5.14	-90.04%	―	-58.33%	-6.14%

* Healthcare Sector Average

Performance Comparison

GB:0JDK and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0JDK	Iovance Biotherapeutics	8.03	5.58	227.55%
NKTR	Nektar Therapeutics	38.44	-15.51	-28.75%
RCUS	Arcus Biosciences	18.80	-0.99	-5.00%
IMTX	Immatics N.V.	6.69	-3.29	-32.97%
NUVB	Nuvation Bio Inc	4.29	-0.40	-8.53%
IMCR	Immunocore Holdings Plc	31.65	-3.72	-10.52%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Iovance Biotherapeutics AI Stock Analysis